NIDA�s New AIDS Research Program by CO324l33

VIEWS: 6 PAGES: 17

									NIDA’s New HIV/AIDS
   Research Program


       Jacques Normand, Ph.D.
   Director, AIDS Research Program
   National Institute on Drug Abuse
                          Objectives
• Update on NIDA’s New AIDS Research
  Program
  – CAMCODA
  – NIDA Council Recommendations
  – New AIDS Research Program
       – Structure
       – Research Priorities
• Brief Update on NIDA/NIH Collaborative
  Projects
  – Projects and Partners
  – New HPTN Network Drug Abuse Projects
  CAMCODA Structure

                       Director

   Deputy
   Director


                                        Population-
  Medical              Human
                                           Based
Consequence          Development        Intervention
   Unit                 Unit                Unit

              Staff: 20 Professionals
NIDA AIDS FY03 AIDS
  Funding by Divisions

CAMCODA     116,035,000

DESPR       57,707,000

DTR&D       54,204,000

DNBR        29,615,000

CTN         12,052,000
   NIDA Advisory Council
Workgroup on HIV/AIDS


           Report on
 Findings and Recommendations
         February, 2004
     Structural & Procedural
           Recommendations
• Create new position of “Director, AIDS Research
  Program” reporting to NIDA’s Director

• Update policy/procedures to determine which projects
  qualify for AIDS funding

• Improve articulation of HIV/AIDS mission and
  planning process within & across Divisions/Centers

• Increase interaction across NIH, and with extramural
  community
           NIDA’s AIDS Research
              Program Structure
                       AIDS Research Program
      Mission: Plan, develop, coordinate and integrate research
               priorities within NIDA and externally.
      Staff:   Jacques Normand
               Lynda Erinoff
               Helen Cesari




     AIDS Workgroup                      External Scientific AIDS Workgroup
AIDS Coding Subgroup                     TBA
       NIDA’s AIDS Workgroup
                 Membership
Division of Pharmacotherapies and Medical
Consequences of Drug Abuse
     Jag Khalsa
     Ahmed Elkashef
     Jamie Biswas
Division of Basic Neurosciences and Behavioral
Research
     Diane Lawrence
     Cora Lee Wetherington
     Charles Sharp
     Yu Lin
     Minda Lynch
       NIDA’s AIDS Workgroup
           Membership (Cont.)
Division of Epidemiology, Services, and Prevention
Research
     Elizabeth Lambert

Division of Clinical Neurosciences, Development and
Behavioral Treatment
     Lisa Onken
     Melissa Racioppo
     Nicolette Borek
     Ro Nemeth

Center for Clinical Trials Network
     Mary Ellen Michel
      NIDA’s AIDS Workgroup
          Membership (Cont.)
Office of Science Policy & Communication
     Anna Staton

International Program
     Steve Gust

Intramural Research Program
     John Schmittner

Office of Extramural Affairs
     Mark Green

Office of Planning & Research Management
     Stacy Gardner
         External Scientific AIDS
                      Workgroup
Proposed Membership (~ 8):
     Council Members
     Nominee per Division/Center
     Nominee from AIDS Program

Proposed Task:
     Review NIDA’s AIDS Strategic Plan
     Review & make recommendations on new AIDS related
     procedural change (e.g., definition of AIDS and coding
     guidelines)
     Review NIDA’s priorities/initiatives
FY04 AIDS Funding by
       NIDA Divisions

 DPMC        52,046,000

 DESPR       121,656,000

 DCNDBT      46,336,000

 DBNBR       29,374,000

 CCTN        11,557,000
NIDA’s FY04 Funding By OAR
  Research Areas of Emphasis
1. Natural History and Epidemiology   $54,246,859
2. Etiology and Pathogenesis          $29,028,598
3. Therapeutics                       $12,084,141
4. Vaccines                           $1,983,201
5. Behavioral and Social Science      $186,583,465
6. Training, Infrastructure, and
   Capacity Building                  $6,860,742
7. Information Dissemination          $1,594,994
                  Research Priority
                 Recommendations
Update programs with continuous review of
epidemiologic and other findings
   Racial/ethnic disparities
   Emphasize case finding/treatment
   HAART interactions/adherence/resistance
   Newer HIV/IDU epidemics (Russia, China, India, Eastern Europe)
   Test drug Tx for HIV prevention
   Emerging drugs (e.g., Meth/Viagra, NYC case/immunological & CNS impact )
   Sexual risk behaviors (main exposure category)
   Adolescents (developmental/decision making, impulsivity)
   Role of drug abuse on transmission (drug type, partnership, context)
              Current NIDA’s AIDS
                    Program Tasks
• Explore new ways to attract new AIDS PIs
• Better integrate HIV/AIDS within and across
  NIDA Divisions/Centers and other NIH Institutes
• Working on Generating FY07 OAR Priorities
 (retooling priorities to establish strong presence in all Div/Ctr)
• Will be Generating NIDA FY06 AIDS Initiatives
• Developing Criteria for AIDS Grants
• Will be Appointing Members to Extramural
  Scientific AIDS Workgroup
• Will be Developing NIDA’s HIV/AIDS Strategic Plan
        NIDA’s Collaborative
                    Projects
  Network/Cohort       Collaborating ICs     NIDA’s Co-Fund

Adolescent Trial
                     NICHD, NIMH           $1.0/20.0M
Network
Pediatric HIV AIDS   NICHD, NIAID,
                                           $3.0/12.0M
Cohort Study         NIMH
Centers For AIDS     NIAID, NCI, NHLBI,
                                           $4.6/33.3M
Research             & NIMH
Women Interagency
                  NIAID, NICHD, & NCI $0.5/18.5M
HIV Study
HIV Prevention       NIAID,NIMH, NICHD,
                                        $4.4/70.0M
Trial Network        & FIC
      HPTN & New NIAID
               Network
• Current Projects
     Epidemiology
     HIV Prevention
     Drug Tx as HIV Prevention

• New Network
     Proposed protocols
           Community Scale-up;
           Stimulant pharmacotherapy as HIV prevention

								
To top